In contrast, and in line with the proposed role of PAK1 in AML pathogenesis, levels of PAK1 are significantly upregulated in a high‐risk group of AML patients (Pandolfi et al, 2015), whereas levels of PAK2 are downregulated (Fig S1B). The gene discussed is PAK2; the disease is acute myeloid leukemia.